GlaxoSmithKline Pharmaceuticals Limited stands as one of India's leading pharmaceutical companies, carrying forward a rich legacy of over a century in the country. The company was incorporated in 1924 and is headquartered in Mumbai, India, with over a century of experience in India. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The company has established itself as a prominent player in the Indian pharmaceutical sector, with a market cap of Rs. 57,225.36 Cr. as of December 6, 2025. The promoter holding stands at 75.0%, indicating strong backing from its parent company GSK plc.
GlaxoSmithKline Pharmaceuticals operates across diverse therapeutic areas, maintaining a comprehensive portfolio of general medicines, specialty medicines, and vaccines. The company, based in Mumbai, manufactures and distributes prescription medicines across therapeutic areas like dermatology, diabetes, and cardiovascular diseases. It also offers vaccines for hepatitis, influenza, chickenpox, and other infectious diseases in India and global markets.
The company's general medicines portfolio includes several market-leading brands. The company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch.
In the specialty medicines segment, the company provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. The company has also made significant strides in the adult vaccination space with the launch of Shingrix, an adult vaccination for the prevention of Herpes Zoster and postherpetic neuralgia (PHN) in 2024.
GlaxoSmithKline Pharmaceuticals has demonstrated strong financial performance in recent quarters. The company's net profit jumped 35.17% since last year same period to ₹262.87Cr in the Q4 2024-2025, while revenue stood at ₹974.37Cr as on March 2025 (Q4 FY25). For the full year, net profit rose 57.23% to Rs 927.58 crore in the year ended March 2025 as against Rs 589.96 crore during the previous year ended March 2024. Sales rose 8.56% to Rs 3749.21 crore in the year ended March 2025 as against Rs 3453.71 crore during the previous year ended March 2024.
The company's financial health is particularly noteworthy, as the company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. An annual revenue growth of 9% is good, Pre-tax margin of 34% is great, ROE of 47% is exceptional.
The company's quarterly performance has been consistently strong. Net profit of GlaxoSmithKline Pharmaceuticals rose 402.80% to Rs 229.88 crore in the quarter ended December 2024 as against Rs 45.72 crore during the previous quarter ended December 2023, while sales rose 17.90% to Rs 949.42 crore in the quarter ended December 2024 as against Rs 805.26 crore during the previous quarter ended December 2023.
The company has maintained its competitive edge through strategic brand management and market share gains. GlaxoSmithKline Pharma continued to benefit from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Moreover, rising demand for its vaccine for shingles has also boosted earnings. The company said that a rising market share of its key brands - Ceftum, Augmentin and Calpol - has helped it mitigate the impact of these price caps.
Despite facing challenges from government price controls, earnings at drugmakers like GlaxoSmithKline Pharma have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022. However, the company has successfully navigated these challenges through strategic initiatives and strong brand performance.
The company has been actively expanding its product portfolio and market reach. In FY2024-25, Company introduced TBact ointment 15g in a new Lami pack format and Becadexamin capsules were launched in a 60s HDPE pack format to improve efficiency. Additionally, the company has forayed into newer segments like emollients with Physiogel, which is now the fourth most prescribed emollient brand among Dermatologists.
Looking ahead, the company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer, demonstrating its commitment to expanding into oncology therapeutics.
GlaxoSmithKline Pharmaceuticals has maintained a consistent dividend policy, rewarding shareholders with regular distributions. The company announces a final dividend of Rs 42 per share for FY25, subject to shareholder approval at the company's 100th Annual General Meeting. The company has been maintaining a healthy dividend payout of 93.1%, reflecting its commitment to returning value to shareholders.
GlaxoSmithKline Pharmaceuticals continues to strengthen its position in the Indian pharmaceutical market through strategic product launches, operational excellence, and a focus on therapeutic areas with high growth potential, making it a significant player in India's evolving healthcare landscape.
